隴神戎發(300534.SZ):大力推進甘肅道地藥材出口
格隆匯7月27日丨有投資者向隴神戎發(300534.SZ)提問:請介紹下目前公司藥品出口的現狀以及未來規劃。
隴神戎發回復:截止目前,上市公司自有產品元胡止痛滴丸、黃芪當歸膠囊、七味温陽膠囊、舒心寧片、消栓通絡片等7個產品已成功在泰國、新加坡、俄羅斯、吉爾吉斯斯坦等國家完成了境外註冊,並取得銷售資質。近年來重點以拓展當歸、黃芪、黨蔘、大黃、甘草等道地中藥材國際市場為主要目標,深入中藥材原產地採購高品質道地藥材,提升中藥材供應能力和質量保障,大力推動甘肅道地藥材出口東南亞、韓國、中國台灣等地區。
未來,公司將進一步把握“一帶一路”發展機遇,大力推進甘肅道地藥材出口,中成藥境外註冊、出口銷售等業務,促進中醫藥在海外市場的發展,擴大公司業務範圍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.